Trevogrumab
Also known as: Trevogrumab
Trevogrumab (REGN1033) is an investigational fully human monoclonal antibody that binds and neutralizes myostatin (GDF-8). It has been studied as an anti-myostatin therapy aimed at preserving or increasing skeletal muscle mass. Note: Trevogrumab is a monoclonal antibody (anti-myostatin), not a peptide; included here for reference.
Last updated
Mechanism of Action
Trevogrumab is an IgG4 monoclonal antibody that selectively binds mature myostatin (growth differentiation factor 8), preventing it from engaging the activin type IIB receptor (ActRIIB). Myostatin normally signals through ActRIIB and the ALK4/ALK5 receptors to activate SMAD2/3, which transcriptionally restrains muscle fiber growth. By sequestering circulating myostatin, the antibody relieves this brake, shifting the balance toward muscle protein accretion and hypertrophy. Because it targets myostatin specifically rather than the shared receptor, it is intended to spare related TGF-beta family signaling.
- Half-life
- Estimated multi-week, consistent with IgG monoclonal antibodies
- Administration Routes
- subcutaneous, intravenous
- Research Status
- Preclinical
Reported Benefits
- Neutralizes myostatin to reduce inhibition of muscle growth
- Investigated for preserving lean mass in age-related sarcopenia
- Studied for muscle wasting associated with disuse and disease
- Highly selective antibody targeting limits off-target receptor effects
- Potential to support muscle mass without androgenic activity
Potential Side Effects
- Injection-site reactions
- Possible immune or hypersensitivity responses to antibody therapy
- Tendon and connective-tissue concerns with rapid mass change
- Limited human safety data outside trials
Common Dosing
Clinical investigation has explored intravenous or subcutaneous dosing in the low milligram-per-kilogram range at multi-week intervals. Provided for research and educational reference only, not as personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Known hypersensitivity to monoclonal antibody products
- Active malignancy without specialist oversight
- Pregnancy and breastfeeding
ACE-031
ACE-031 is a soluble decoy receptor (ActRIIB-Fc fusion) studied as a myostatin inhibitor to increase muscle mass and strength.
Myostatin
Myostatin (GDF-8) is a naturally occurring protein that limits skeletal muscle growth. In the research and peptide market the term commonly refers to myostatin-inhibitor compounds intended to block this growth-limiting signal. Note: Myostatin (GDF-8) is a protein that LIMITS muscle growth; research interest centers on inhibiting it, not administering it.
Follistatin 344
Follistatin 344 is the full-length precursor isoform of follistatin studied for blocking myostatin and activin to drive muscle growth and tissue repair.
- View
GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial
2025
- View
Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice
2015
- View
Activin A more prominently regulates muscle mass in primates than does GDF8
2017
- View
GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates
2025